Fusen Pharmaceutical Co., Ltd. (HK:1652) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Fusen Pharmaceutical Co. Ltd. has announced the acceptance of its application by China’s National Medical Products Administration to launch ‘Enzalutamide Soft Capsules,’ a new treatment for prostate cancer. The drug, developed by a subsidiary of the company, is aimed at patients with non-metastatic and metastatic castration-resistant prostate cancer. This addition is set to expand the company’s anti-tumor therapy portfolio and offer more options for prostate cancer treatment.
For further insights into HK:1652 stock, check out TipRanks’ Stock Analysis page.